WO2009018198A1 - Endoparasiticidal topical compositions - Google Patents

Endoparasiticidal topical compositions Download PDF

Info

Publication number
WO2009018198A1
WO2009018198A1 PCT/US2008/071311 US2008071311W WO2009018198A1 WO 2009018198 A1 WO2009018198 A1 WO 2009018198A1 US 2008071311 W US2008071311 W US 2008071311W WO 2009018198 A1 WO2009018198 A1 WO 2009018198A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
macrocyclic lactone
praziquantel
composition
amount
Prior art date
Application number
PCT/US2008/071311
Other languages
French (fr)
Inventor
Nahla Fattohi
Moses Columbus Lawrence
Shobhan Shashikant Sabnis
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Priority to BRPI0814165-7A2A priority Critical patent/BRPI0814165A2/en
Priority to JP2010520107A priority patent/JP2010535231A/en
Priority to AU2008282388A priority patent/AU2008282388A1/en
Priority to CA2694485A priority patent/CA2694485A1/en
Priority to CN200880101085A priority patent/CN101854926A/en
Priority to EP08796686A priority patent/EP2170308A1/en
Priority to MX2010001188A priority patent/MX2010001188A/en
Publication of WO2009018198A1 publication Critical patent/WO2009018198A1/en
Priority to ZA2010/01433A priority patent/ZA201001433B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Definitions

  • Worms are the most common endoparasites of companion animals and infestations of worms are among the most critical of parasitic infestations in cats and dogs.
  • Modern endoparasiticidal agents such as moxidectin and praziquantel, have a wide margin of safety, considerable activity against immature or larval stages of parasites and a broad spectrum of activity. Nonetheless, the usefulness of any endoparasiticidal agent is limited by the inherent efficacy of the drug itself, its mechanism of action, its pharmacokinetic properties, features relating to the host animal, features relating to the target parasites and the form of administration.
  • endoparasiticidal agents such as praziquantel and a macrocyclic lactone such as moxidectin
  • a veterinarian for effective control are administered orally as a tablet or parenterally by a veterinarian.
  • the "ideal" endoparasiticidal administrative form should have a broad spectrum of activity against mature and immature parasites, be easy to administer to companion animals, have a wide margin of safety, be compatible with other compounds, not require the assistance of a veterinarian and be economical.
  • a further complication to the formulation of endoparasiticidal agents for use with companion animals is the cosmetic acceptability and non- irritability of the formulation when applied to the animal.
  • an acceptable formulation must be sufficiently easy to apply, dry within a reasonable period of time without impairment of the animal's appearance, be gentle on the animal's coat, non-irritating to the animal's skin and maintain its effectiveness on the animal through normal activities of the animal, such as exposure to sun and water. It must also be able to be applied to the animal in a small enough volume so that it can be applied so as to avoid the animal licking the area of application.
  • the composition will provide the active ingredients in a formulation which will have at least a sufficient duration of activity, so as to avoid the necessity of frequent reapplication during this period of time.
  • praziquantel is not highly soluble, and this characteristic has limited the development of veterinary compositions containing high concentrations of praziquantel. Therefore, it is an object of this invention to provide a topical, endoparasiticidal veterinary composition containing (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid or a combination thereof, which allows sufficiently high concentrations of each of the active ingredients and which is stable. It is another object of the invention to provide a method for the prevention, treatment and control of endoparasiticidal infection or infestation in an animal, particularly a companion animal. It is a further object of the invention to provide a broad spectrum gastro-intestinal worm treatment with simple stress-free topical application.
  • compositions provided offer high concentrations of active agents for maximum efficacy.
  • the present invention provides a composition which comprises: an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier.
  • Topical veterinary compositions require relatively high concentrations of active ingredients to ensure effective and long-lasting protection to the host animal and administration in sufficiently small volumes so as to avoid loss of the composition from run-off or licking by the animal.
  • Typical "spot-on" applications of such compositions to the base of the neck of the animal aid in making the applied composition difficult for the animal to remove, but require that a relatively small volume be applied.
  • the solubility of praziquantel frequently limits the abilitly to obtain high concentrations of praziquantel in such applications.
  • Topical veterinary compositions containing praziquantel as one of the active ingredients are highly desirable due to the effective and persistent activity of praziquantel against a wide variety of intestinal worms.
  • praziquantel and a macrocyclic lactone such as moxidectin may be formulated in a stable topical non-irritating composition by employing as a carrier 4-allyl-2-methoxyphenol.
  • the present invention provides a topical veterinary endoparasiticidal composition which comprises: an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier.
  • Macrocyclic lactones are one chemical class of anthelmintics.
  • a macrocyclic lactone may be an avermectin or a milbemycin or a combination thereof.
  • Macrocyclic lactones, such as avermectins and milbemycins, are products, or chemical derivatives thereof, of soil microorganisms belonging to the genus Streptomyces.
  • Such macrocyclic lactones are endoparasiticidal agents that are active against many immature nematodes and arthropods.
  • Macrocyclic lactones suitable for use in the composition of the invention include: avermectins, such as abamectin, doramectin, ivermectin, selamectin or eprinomectin; and milbemycins, such as moxidectin or milbemycin oxime, or the like, preferably moxidectin.
  • avermectins such as abamectin, doramectin, ivermectin, selamectin or eprinomectin
  • milbemycins such as moxidectin or milbemycin oxime, or the like, preferably moxidectin.
  • compositions of the present invention may include imidacloprid.
  • Imidacloprid is a systemic insecticide.
  • the effective amounts of praziquantel and the macrocyclic lactone may be up to as high as 20% w/v of the total composition.
  • praziquantel may be present at about 10- 15% w/v, preferably 10-12% w/v
  • the macrocyclic lactone may be present at about 1.0-5.0% w/v, preferably 2.0-3.0% w/v.
  • the effective amounts may vary according to the potency of the compounds, the method of application, the host animal, the target parasite, the degree of infestation, or the like. It is understood that effective amounts of less than 20% may be suitable for the composition of the invention.
  • compositions when administered in the form of a pour-on, spray or any topical administration suitable for use in large animals such as swine, sheep, horses or cattle, amounts of about 0.5-3.0% w/v, preferably 1.0-2.5% w/v, of praziquantel may be suitable and amounts of about 0.01-2.0% w/v, preferably 0.1-1.0 % w/v, more preferably 0.5% w/v, of the macrocyclic lactone may be suitable.
  • w/w designates weight/weight
  • w/v designates weight/volume
  • mg/kg designates milligrams per kilogram of body weight
  • the 4-allyl-2-methoxyphenol carrier component is present in the topical veterinary compositions in an amount of about 20-70% w/v, preferably 25-65% w/v. In another embodiment, the 4-allyl-2-methoxyphenol carrier component is preferably present in the topical veterinary compositions in a minimum amount of about 20-30% w/v.
  • the topical composition of the invention may also include one or more additional ingredients.
  • suitable additional ingredients include: stabilizers such as butylated hydroxytoluene, penetration enhancers such as polyglycolysed glycerides, e.g.
  • LABRASOLTM anti-crystallizing agents such as polyvinylpyrrolidone (PVP); antioxidants; spreading agents, such as Crodamol PMPTM; preservatives; adhesion promoters; viscosity modifiers such as polybutene polymers; UV blockers or absorbers; colourants; surface active agents, including anionic, cationic, non- ionic and ampholytic surface active agents; and those excipients conventionally employed in veterinary topical compositions.
  • PVP polyvinylpyrrolidone
  • spreading agents such as Crodamol PMPTM
  • preservatives such as Crodamol PMPTM
  • adhesion promoters such as polybutene polymers
  • viscosity modifiers such as polybutene polymers
  • UV blockers or absorbers colourants
  • surface active agents including anionic, cationic, non- ionic and ampholytic surface active agents
  • excipients conventionally employed in veterinary topical compositions for example stabilizers, such as
  • Penetration enhancers such as polyglycolysed glycerides may be present in the inventive compositon in amounts of about 0-40% w/v, preferably about 0-30% w/v.
  • Anti- crystallizing agents such as polyvinylpyrrolidone may be present in the inventive composition in amounts of about 0-5%, preferably about 0.1-5.0%.
  • the composition of the invention may further comprise a co-solvent such as ⁇ -hexalactone or triethyl citrate.
  • the co-solvent may be present in the composition of the invention in amounts of about 5.0-40% w/v, preferably about 15-30% w/v, more preferably about 20-26% w/v.
  • Excipients such as dyes, antimicrobial agents, antioxidants or mixtures thereof may be included in the composition of the invention. The amounts of said excipients suitable for use in the invention range from about 0-2.0% w/v.
  • the endoparasiticidal topical veterinary composition of the invention allows for high concentrations of the active ingredients and demonstrates no irritation to the skin/hide/hair of the host animal.
  • the present invention provides a method for the treatment of an endoparasiticidal infection or infestation in a homeothermic animal, which comprises topically administering to said animal a composition which comprises an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2- methoxyphenol as carrier.
  • topical administrations suitable for use in the method of the invention include spot-on, pour-on, dip, wash, shampoo, foam, gel, lotion, or any of the conventional means of topically applying a liquid veterinary composition.
  • the topical mode or administration will vary with the species and size of the host animal.
  • companion animals such as dogs or cats
  • a spot-on, gel, shampoo or wash preferably a spot-on
  • a pour-on or spray preferably a pour-on
  • Homeothermic animals suitable for treatment using the composition and method of the present invention include: swine, cattle, sheep, horses, goats, camels, water buffalos, donkeys, rabbits, fallow deer, reindeer, minks, chinchillas, raccoons, chicken, geese, turkeys, ducks, dogs, cats, or the like, preferably dogs, cats, swine, cattle, horses or sheep.
  • Endoparasitic infection or infestations suitable for treatment by the method of the invention include tapeworms, strongyles, Eencysted Cyathostomes, pinworms, hairworms, whipworms, ascarids, large-mouth stomach worms, bots or the like.
  • the composition of the invention may be administered in dose rates of mg of active ingredient per kg of body weight of the host animal. Dose rates suitable for use in the method of invention will vary depending upon the mode of administration, the species and health of the host animal, the target parasite, the degree of infection or infestation, the breeding habitat, the potency of the macrocyclic lactone, and the like.
  • amounts of said composition sufficient to provide about 8.0 mg/kg to 15.0 mg/kg, preferably about 10mg/kg to 12mg/kg of praziquantel per body weight of the animal and about 0.5 mg/kg to 3.5 mg/kg, preferably about 1.0 mg/kg to 2.5 mg/kg of a macrocyclic lactone such as moxidectin per body weight of the animal and are suitable.
  • Macrocyclic lactones suitable for use in the method of the invention include: avermectins such as abamectin, doramectin, ivermectin, selamectin or eprinomectin; milbemycins such as moxidectin or milbemycin oxime, or the like, preferably moxidectin.
  • the dry ingredients such as moxidectin, praziquantel, BHT and PVP are mixed together and shaken until well dispersed.
  • the resultant solid mixture is treated with the remaining liquid ingredients and stirred until a clear homogeneous solution is obtained.
  • test compositions prepared in Example 2 are administered to three dogs per treatment group by spotting the test composition between the front shoulders of the test animal at volumes providing a dose rate of 12 mg/kg of praziquantel and 2.5mg/kg of moxidectin. Serum levels of moxidectin were determined at 3, 7 and 10 days after treatment (DAT). The results are shown in Table I. All test compositions showed acceptable appearance, when applied on dogs, 48 hours after treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a composition which comprises: an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier. Also provided is a method for the treatment of endoparasitic infection and infestation in a homeothermic animal.

Description

ENDOPARASITICIDAL TOPICAL COMPOSITIONS
BACKGROUND
Worms are the most common endoparasites of companion animals and infestations of worms are among the most critical of parasitic infestations in cats and dogs. Modern endoparasiticidal agents, such as moxidectin and praziquantel, have a wide margin of safety, considerable activity against immature or larval stages of parasites and a broad spectrum of activity. Nonetheless, the usefulness of any endoparasiticidal agent is limited by the inherent efficacy of the drug itself, its mechanism of action, its pharmacokinetic properties, features relating to the host animal, features relating to the target parasites and the form of administration.
In general, endoparasiticidal agents, such as praziquantel and a macrocyclic lactone such as moxidectin, for effective control are administered orally as a tablet or parenterally by a veterinarian. The "ideal" endoparasiticidal administrative form should have a broad spectrum of activity against mature and immature parasites, be easy to administer to companion animals, have a wide margin of safety, be compatible with other compounds, not require the assistance of a veterinarian and be economical. A further complication to the formulation of endoparasiticidal agents for use with companion animals is the cosmetic acceptability and non- irritability of the formulation when applied to the animal. Obviously, an acceptable formulation must be sufficiently easy to apply, dry within a reasonable period of time without impairment of the animal's appearance, be gentle on the animal's coat, non-irritating to the animal's skin and maintain its effectiveness on the animal through normal activities of the animal, such as exposure to sun and water. It must also be able to be applied to the animal in a small enough volume so that it can be applied so as to avoid the animal licking the area of application. Most desirably, the composition will provide the active ingredients in a formulation which will have at least a sufficient duration of activity, so as to avoid the necessity of frequent reapplication during this period of time. However, praziquantel is not highly soluble, and this characteristic has limited the development of veterinary compositions containing high concentrations of praziquantel. Therefore, it is an object of this invention to provide a topical, endoparasiticidal veterinary composition containing (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid or a combination thereof, which allows sufficiently high concentrations of each of the active ingredients and which is stable. It is another object of the invention to provide a method for the prevention, treatment and control of endoparasiticidal infection or infestation in an animal, particularly a companion animal. It is a further object of the invention to provide a broad spectrum gastro-intestinal worm treatment with simple stress-free topical application.
An additional feature of this invention is that the compositions provided offer high concentrations of active agents for maximum efficacy. Other objects and features of the invention will be come more apparent from the detailed description set forth hereinbelow.
SUMMARY
The present invention provides a composition which comprises: an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier.
Also provided is a method for the treatment of endoparasitic infection and infestation in a homeothermic animal.
DETAILED DESCRIPTION
Many topical veterinary compositions require relatively high concentrations of active ingredients to ensure effective and long-lasting protection to the host animal and administration in sufficiently small volumes so as to avoid loss of the composition from run-off or licking by the animal. Typical "spot-on" applications of such compositions to the base of the neck of the animal aid in making the applied composition difficult for the animal to remove, but require that a relatively small volume be applied. However, the solubility of praziquantel frequently limits the abilitly to obtain high concentrations of praziquantel in such applications. Topical veterinary compositions containing praziquantel as one of the active ingredients are highly desirable due to the effective and persistent activity of praziquantel against a wide variety of intestinal worms.
Surprisingly, it has now been found that praziquantel and a macrocyclic lactone such as moxidectin may be formulated in a stable topical non-irritating composition by employing as a carrier 4-allyl-2-methoxyphenol. Accordingly, the present invention provides a topical veterinary endoparasiticidal composition which comprises: an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier.
Macrocyclic lactones are one chemical class of anthelmintics. As an example, "a macrocyclic lactone" may be an avermectin or a milbemycin or a combination thereof. Macrocyclic lactones, such as avermectins and milbemycins, are products, or chemical derivatives thereof, of soil microorganisms belonging to the genus Streptomyces. Such macrocyclic lactones are endoparasiticidal agents that are active against many immature nematodes and arthropods. Macrocyclic lactones suitable for use in the composition of the invention include: avermectins, such as abamectin, doramectin, ivermectin, selamectin or eprinomectin; and milbemycins, such as moxidectin or milbemycin oxime, or the like, preferably moxidectin.
The topical veterinary compositions of the present invention may include imidacloprid. Imidacloprid is a systemic insecticide.
The effective amounts of praziquantel and the macrocyclic lactone may be up to as high as 20% w/v of the total composition. For example, praziquantel may be present at about 10- 15% w/v, preferably 10-12% w/v, and the macrocyclic lactone may be present at about 1.0-5.0% w/v, preferably 2.0-3.0% w/v. The effective amounts may vary according to the potency of the compounds, the method of application, the host animal, the target parasite, the degree of infestation, or the like. It is understood that effective amounts of less than 20% may be suitable for the composition of the invention. For example when the composition is administered in the form of a pour-on, spray or any topical administration suitable for use in large animals such as swine, sheep, horses or cattle, amounts of about 0.5-3.0% w/v, preferably 1.0-2.5% w/v, of praziquantel may be suitable and amounts of about 0.01-2.0% w/v, preferably 0.1-1.0 % w/v, more preferably 0.5% w/v, of the macrocyclic lactone may be suitable.
As used herein, the term "w/w" designates weight/weight, "w/v" designates weight/volume, and the term "mg/kg" designates milligrams per kilogram of body weight.
In one embodiment, the 4-allyl-2-methoxyphenol carrier component is present in the topical veterinary compositions in an amount of about 20-70% w/v, preferably 25-65% w/v. In another embodiment, the 4-allyl-2-methoxyphenol carrier component is preferably present in the topical veterinary compositions in a minimum amount of about 20-30% w/v.
In addition to a carrier system consisting essentially of 4-allyl-2-methoxyphenol and the active agents, praziquantel and a macrocyclic lactone such as moxidectin, the topical composition of the invention may also include one or more additional ingredients. Examples of suitable additional ingredients include: stabilizers such as butylated hydroxytoluene, penetration enhancers such as polyglycolysed glycerides, e.g. LABRASOL™; anti-crystallizing agents such as polyvinylpyrrolidone (PVP); antioxidants; spreading agents, such as Crodamol PMP™; preservatives; adhesion promoters; viscosity modifiers such as polybutene polymers; UV blockers or absorbers; colourants; surface active agents, including anionic, cationic, non- ionic and ampholytic surface active agents; and those excipients conventionally employed in veterinary topical compositions. For example stabilizers, such as butylated hydroxytoluene, may be present in the composition of the invention in amounts of about 0-5% w/v, preferably about 0.1-1.0% w/v. Penetration enhancers such as polyglycolysed glycerides may be present in the inventive compositon in amounts of about 0-40% w/v, preferably about 0-30% w/v. Anti- crystallizing agents such as polyvinylpyrrolidone may be present in the inventive composition in amounts of about 0-5%, preferably about 0.1-5.0%. In one embodiment, the composition of the invention may further comprise a co-solvent such as γ-hexalactone or triethyl citrate. The co-solvent may be present in the composition of the invention in amounts of about 5.0-40% w/v, preferably about 15-30% w/v, more preferably about 20-26% w/v. Excipients such as dyes, antimicrobial agents, antioxidants or mixtures thereof may be included in the composition of the invention. The amounts of said excipients suitable for use in the invention range from about 0-2.0% w/v.
Advantageously, the endoparasiticidal topical veterinary composition of the invention allows for high concentrations of the active ingredients and demonstrates no irritation to the skin/hide/hair of the host animal. Accordingly, the present invention provides a method for the treatment of an endoparasiticidal infection or infestation in a homeothermic animal, which comprises topically administering to said animal a composition which comprises an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2- methoxyphenol as carrier.
Examples of topical administrations suitable for use in the method of the invention include spot-on, pour-on, dip, wash, shampoo, foam, gel, lotion, or any of the conventional means of topically applying a liquid veterinary composition. The topical mode or administration will vary with the species and size of the host animal. As an example, for companion animals such as dogs or cats, a spot-on, gel, shampoo or wash, preferably a spot-on, may be suitable. For large agronomic animals such as cattle, horses or sheep, a pour-on or spray, preferably a pour-on, may be suitable.
Homeothermic animals suitable for treatment using the composition and method of the present invention include: swine, cattle, sheep, horses, goats, camels, water buffalos, donkeys, rabbits, fallow deer, reindeer, minks, chinchillas, raccoons, chicken, geese, turkeys, ducks, dogs, cats, or the like, preferably dogs, cats, swine, cattle, horses or sheep.
Endoparasitic infection or infestations suitable for treatment by the method of the invention include tapeworms, strongyles, Eencysted Cyathostomes, pinworms, hairworms, whipworms, ascarids, large-mouth stomach worms, bots or the like. In actual practice, the composition of the invention may be administered in dose rates of mg of active ingredient per kg of body weight of the host animal. Dose rates suitable for use in the method of invention will vary depending upon the mode of administration, the species and health of the host animal, the target parasite, the degree of infection or infestation, the breeding habitat, the potency of the macrocyclic lactone, and the like. In general, amounts of said composition sufficient to provide about 8.0 mg/kg to 15.0 mg/kg, preferably about 10mg/kg to 12mg/kg of praziquantel per body weight of the animal and about 0.5 mg/kg to 3.5 mg/kg, preferably about 1.0 mg/kg to 2.5 mg/kg of a macrocyclic lactone such as moxidectin per body weight of the animal and are suitable.
Macrocyclic lactones suitable for use in the method of the invention include: avermectins such as abamectin, doramectin, ivermectin, selamectin or eprinomectin; milbemycins such as moxidectin or milbemycin oxime, or the like, preferably moxidectin.
For a more clear understanding of the invention, the following examples are set forth hereinbelow. These examples are merely illustrative and are not understood to limit the scope or underlying principles of the invention in any way. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the examples set forth hereinbelow and the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
Unless otherwise designated, all parts are parts by weight. The term qs designates quantity sufficient to obtain a total of 100%.
EXAMPLES
EXAMPLE 1 : Preparation of Endoparasiticidal Compositions
Component A B C D Description
%w/w %w/w %w/w %w/w
Praziquantel 10.50 10.53 1 1.80 11.9
Moxidectin 2.2 2.2 2.5 2.5
BHT* 0.40 0.45 0.50 0.50
Crodamol PMPn — 22.77 — —
LAB RASO L™** 27.5 9.54 — —
Eugenol*** 27.5 54.18 60.34 60.10 γ-Hexalactone qs — qs —
Triethyl Citrate — — — qs
*Butylated hydroxytoluene **polyglycolysed glycerides
***4-allyl-2-methoxyphenol nPPG-2 Myristyl Ether Propionate Method of Preparation
The dry ingredients, such as moxidectin, praziquantel, BHT and PVP are mixed together and shaken until well dispersed. The resultant solid mixture is treated with the remaining liquid ingredients and stirred until a clear homogeneous solution is obtained.
EXAMPLE 2: Preparation of Endoparasiticidal Compositions
Using essentially the same procedure described in Example 1 hereinabove, the compositons shown below are prepared.
Component A B C D Description
%w/v %w/v %w/v %w/v
Praziquantel 12.0 12.0 12.0 12.0
Moxidectin 2.50 2.50 2.50 2.5
BHT* 0.50 0.50 0.50 0.5
Plasdone K- — — — 3.2
29/32**
LABRASOL™*** 29.0 — — —
Eugenol**** 30.0 65.0 65.0 65.0 γ-Hexalactone qs qs — qs
Triethyl Citrate — — qs — *Butylated hydroxytoluene "Polyvinylpyrrolidone (PVP) ***polyglycolysed glycerides ****4-allyl-2-methoxyphenol
EXAMPLE 3: Evaluation of the Plasma Levels of Test Compositions
In this evaluation, test compositions prepared in Example 2 are administered to three dogs per treatment group by spotting the test composition between the front shoulders of the test animal at volumes providing a dose rate of 12 mg/kg of praziquantel and 2.5mg/kg of moxidectin. Serum levels of moxidectin were determined at 3, 7 and 10 days after treatment (DAT). The results are shown in Table I. All test compositions showed acceptable appearance, when applied on dogs, 48 hours after treatment.
TABLE I
CANINE SERUM LEVELS OF MOXIDECTIN Body Test Dose Serum Moxidectin (PPb) Wt. Comp. mg/kg (kg) Prazi/Moxi 3 DAT 7 DAT 10 DAT
14.2 2A 12.0/2.5 8.79 1 1.0 7.58
9.7 2A 12.0/2.5 29.3 27.0 21.2
8.1 2A 12.0/2.5 11.3 13.1 6.37
13.6 2B 12.0/2.5 7.8 6.01 5.97
12.6 2B 12.0/2.5 6.33 7.93 6.21
8.7 2B 12.0/2.5 3.00 3.53 3.09
12.0 2C 12.0/2.5 7.22 6.12 7.40
10.1 2C 12.0/2.5 4.55 5.23 5.03
9.0 2C 12.0/2.5 7.18 8.30 5.35

Claims

What is claimed is:
1. A topical veterinary composition which comprises; an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier.
2. The composition according to claim 1 wherein the macrocyclic lactone is selected from abamectin; doramectin; ivermectin; selamectin; eprinomectin; moxidectin and milbemycin oxime.
3. The composition according to claim 2 wherein the macrocyclic lactone is moxidectin.
4. The composition according to any one of claims 1 to 3 wherein the effective amount of the macrocyclic lactone is about 1.0-5.0% w/v.
5. The composition according to claim 4 wherein the effective amount of macrocyclic lactone is about 2.0-3.0% w/v.
6. The composition according to any one of claims 1 to 5 wherein the effective amount of praziquantel is about 10-15% w/v.
7. The composition according to any one of claims 1 to 5 wherein the effective amount of praziquantel is about 10-12% w/v.
8. The composition according to any one of claims 1-7 wherein the 4-allyl-2- methoxyphenol carrier component is present in an amount of about 20-70% w/v.
9. The composition according to any one of claims 1-7 wherein the 4-allyl-2- methoxyphenol carrier component is present in a minimum amount of about 20-30% w/v.
10. The composition according to any one of claims 1 to 9 further comprising a penetration enhancer, and/or a stabilizer and/or a co-solvent.
11. The composition according to claim 10 wherein the penetration enhancer is polyglycolysed glycerides and is present in the amount of up to about 40% w/v.
12. The composition according to claim 1 1 wherein the penetration enhancer is present in the amount of up to about 30% w/v.
13. The composition according to any one of claims 10 to 12 wherein the stabilizer is butylated hydroxytoluene and is present in the amount of up to about 5% w/v.
14. The composition according to claim 13 wherein the stabilizer is present in the amount of about 0.1-1.0% w/v.
15. The composition according to any one of claims 10 to 12 wherein the co-solvent is γ-hexalactone and is present in the amount of about 5.0-40% w/v.
16. A method for the treatment of endoparasiticidal infection or infestation in a homeothermic animal which comprises topically administering to said animal a composition which comprises: an effective amount of (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof; and (c) 4-allyl-2-methoxyphenol as carrier.
17. The method according to claim 16 wherein said composition is administered as a spot-on, pour-on, dip, wash, gel, shampoo, spray, foam, or lotion.
18. The method according to claim 16 or 17 wherein said animal is selected from the group consisting of dogs; cats; swine, cattle; horses; and sheep.
19. The method according to any one of claims 16 to 18 wherein said endoparasiticidal infection or infestation is caused by tapeworms, strongyles, Eencysted Cyathostomes, pinworms, hairworms, whipworms, ascarids, large-mouth stomach worms or bots.
20. The method according to claim 16 wherein the macrocyclic lactone is moxidectin.
21. The method according to claim 20 wherein said animal is a dog or cat.
22. A process for the preparation of a composition according to claim 1 which comprises admixing (a) praziquantel and (b) a second endoparasiticidal agent selected from the group consisting of a macrocyclic lactone, imidacloprid and a combination thereof to give a homogeneous dispersion; treating said dispersion with (c) 4-allyl-2-methoxyphenol to form a mixture; and stirring said mixture to obtain a clear solution.
PCT/US2008/071311 2007-07-31 2008-07-28 Endoparasiticidal topical compositions WO2009018198A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0814165-7A2A BRPI0814165A2 (en) 2007-07-31 2008-07-28 TOPICAL COMPOSITIONS ENDOPARASITICIDES
JP2010520107A JP2010535231A (en) 2007-07-31 2008-07-28 Internal parasite control topical composition
AU2008282388A AU2008282388A1 (en) 2007-07-31 2008-07-28 Endoparasiticidal topical compositions
CA2694485A CA2694485A1 (en) 2007-07-31 2008-07-28 Endoparasiticidal topical compositions
CN200880101085A CN101854926A (en) 2007-07-31 2008-07-28 Endoparasiticidal topical compositions
EP08796686A EP2170308A1 (en) 2007-07-31 2008-07-28 Endoparasiticidal topical compositions
MX2010001188A MX2010001188A (en) 2007-07-31 2008-07-28 Endoparasiticidal topical compositions.
ZA2010/01433A ZA201001433B (en) 2007-07-31 2010-02-26 Endoparasiticidal topical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96275407P 2007-07-31 2007-07-31
US60/962,754 2007-07-31

Publications (1)

Publication Number Publication Date
WO2009018198A1 true WO2009018198A1 (en) 2009-02-05

Family

ID=39925006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071311 WO2009018198A1 (en) 2007-07-31 2008-07-28 Endoparasiticidal topical compositions

Country Status (14)

Country Link
US (1) US20090036458A1 (en)
EP (1) EP2170308A1 (en)
JP (1) JP2010535231A (en)
KR (1) KR20100038118A (en)
CN (1) CN101854926A (en)
AR (1) AR067751A1 (en)
AU (1) AU2008282388A1 (en)
BR (1) BRPI0814165A2 (en)
CA (1) CA2694485A1 (en)
CL (1) CL2008002206A1 (en)
MX (1) MX2010001188A (en)
TW (1) TW200930371A (en)
WO (1) WO2009018198A1 (en)
ZA (1) ZA201001433B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126857A1 (en) * 2009-04-28 2010-11-04 Wyeth Llc Parasiticidal combinations of macrocyclic lactones and polyether antibiotics
CN102481279A (en) * 2009-03-27 2012-05-30 奴布卢克实验室有限公司 A topical parasiticide composition
JP2013523773A (en) * 2010-04-02 2013-06-17 メリアル リミテッド Parasiticidal compositions comprising a plurality of active agents and methods and uses thereof
US9877950B2 (en) 2011-09-12 2018-01-30 Merial Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
WO2018029487A1 (en) * 2016-08-12 2018-02-15 Norbrook Laboratories Limited Moxidectin topical liquid formulations

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003720A (en) * 2008-10-08 2011-04-28 Wyeth Llc Benzimidazole anthelmintic compositions.
US8980896B2 (en) * 2009-12-17 2015-03-17 Merial, Inc. Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
CN102133173B (en) * 2011-03-03 2013-04-03 浙江海正药业股份有限公司 Moxidectin pour sprinkling preparation and preparation method thereof
AR104691A1 (en) * 2016-05-18 2017-08-09 Labyes De Uruguay S A VETERINARY COMPOSITION OF IMIDACLOPRID, MOXIDECTINE AND PRAZIQUANTEL OF CUTANEOUS TOPIC ADMINISTRATION (SPOT ON) FOR TREATMENT AND PREVENTION OF ECTO AND ENDOPARASITOSIS AFFECTING DOGS
EP3815677B1 (en) 2019-10-30 2023-08-30 KRKA, d.d., Novo mesto Stable veterinary composition comprising moxidectin and imidacloprid
US10857151B1 (en) * 2020-02-21 2020-12-08 Villya LLC Treatment of female genital schistosomiasis
CN115813872A (en) * 2022-12-27 2023-03-21 佛山市南海东方澳龙制药有限公司 Compound ivermectin insect repellent tablet for animals and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717993A2 (en) * 1994-11-28 1996-06-26 Virbac S.A. Anthelmintic compositions for equidae
WO2005074965A1 (en) * 2004-02-06 2005-08-18 Vojin Gligovic Application of natural and synthetic eugenol and essential oils from cloves, pimentos and cinnamon leaves for the prevention and treatment of animal diseases caused by bacteria, fungi and parasites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0717993A2 (en) * 1994-11-28 1996-06-26 Virbac S.A. Anthelmintic compositions for equidae
WO2005074965A1 (en) * 2004-02-06 2005-08-18 Vojin Gligovic Application of natural and synthetic eugenol and essential oils from cloves, pimentos and cinnamon leaves for the prevention and treatment of animal diseases caused by bacteria, fungi and parasites

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9237751B2 (en) 2009-03-27 2016-01-19 Norbrook Laboratories Limited Topical parasiticide composition
CN102481279A (en) * 2009-03-27 2012-05-30 奴布卢克实验室有限公司 A topical parasiticide composition
JP2012521978A (en) * 2009-03-27 2012-09-20 ノーアブルック ラボラトリーズ リミテッド Topical parasiticidal composition
WO2010126857A1 (en) * 2009-04-28 2010-11-04 Wyeth Llc Parasiticidal combinations of macrocyclic lactones and polyether antibiotics
JP2017036332A (en) * 2010-04-02 2017-02-16 メリアル インコーポレイテッド Parasiticidal compositions comprising multiple active agents, methods and uses thereof
US9173403B2 (en) 2010-04-02 2015-11-03 Merial, Inc. Parasiticidal compositions comprising multiple active agents, methods and uses thereof
JP2013523773A (en) * 2010-04-02 2013-06-17 メリアル リミテッド Parasiticidal compositions comprising a plurality of active agents and methods and uses thereof
US9770449B2 (en) 2010-04-02 2017-09-26 Merial Inc. Parasiticidal compositions comprising multiple active agents, methods and uses thereof
US9877950B2 (en) 2011-09-12 2018-01-30 Merial Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
US10383854B2 (en) 2011-09-12 2019-08-20 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
US10786487B2 (en) 2011-09-12 2020-09-29 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
US11464763B2 (en) 2011-09-12 2022-10-11 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
WO2018029487A1 (en) * 2016-08-12 2018-02-15 Norbrook Laboratories Limited Moxidectin topical liquid formulations

Also Published As

Publication number Publication date
KR20100038118A (en) 2010-04-12
JP2010535231A (en) 2010-11-18
AU2008282388A1 (en) 2009-02-05
CL2008002206A1 (en) 2008-10-10
MX2010001188A (en) 2010-06-01
AR067751A1 (en) 2009-10-21
TW200930371A (en) 2009-07-16
BRPI0814165A2 (en) 2015-01-20
US20090036458A1 (en) 2009-02-05
CA2694485A1 (en) 2009-02-05
ZA201001433B (en) 2010-11-24
CN101854926A (en) 2010-10-06
EP2170308A1 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
US20090036458A1 (en) Endoparasiticidal topical compositions
AU2003205887B2 (en) Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
NZ510678A (en) Antiparasitic formulations containing avermectin and di-glycol monomethyl ether
AU2006322120B2 (en) Benzimidazole non-aqueous compositions
JP4677405B2 (en) Anthelmintic composition
GB2386067A (en) Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species
AU2006100661B4 (en) Topical formulation
AU634325B2 (en) Pour-on formulations effective for the control of internal and external parasites of homothermic animals
NZ537760A (en) Worming formulations comprising a macrocyclic lactone and piperonyl butoxide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880101085.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08796686

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008282388

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 582691

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008796686

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2694485

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010520107

Country of ref document: JP

Ref document number: MX/A/2010/001188

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008282388

Country of ref document: AU

Date of ref document: 20080728

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107004400

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0814165

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100128